Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Estradiol Benzoate: Advanced Insights for Estrogen Recept...
2025-10-01
Explore the molecular mechanisms and advanced applications of Estradiol Benzoate, a synthetic estradiol analog and estrogen receptor alpha agonist, in estrogen receptor signaling research. This article delivers unique perspectives on hormone receptor binding assays and translational endocrinology.
-
SP600125: Advanced JNK Inhibitor Workflows for Translatio...
2025-09-30
Unlock the power of SP600125, a highly selective ATP-competitive JNK inhibitor, for dissecting MAPK signaling in inflammation, apoptosis, and cancer models. This guide delivers actionable workflows, troubleshooting tactics, and advanced use-cases, elevating your experimental precision in cytokine modulation and phosphoproteomic profiling.
-
SP600125: Advanced JNK Inhibition in Apoptosis and Neurod...
2025-09-29
Explore the unique scientific applications of SP600125, a potent JNK inhibitor, in apoptosis assays and neurodegenerative disease models. This in-depth guide goes beyond pathway dissection to detail mechanistic insights and translational research opportunities.
-
SP600125: Advanced Chemoproteomic Applications in JNK Pat...
2025-09-28
Explore the advanced use of SP600125 as a selective JNK inhibitor in chemoproteomic profiling and MAPK pathway inhibition. Discover how this compound enables new insights into translational control, kinase cross-talk, and disease modeling beyond traditional applications.
-
SP600125 in Translational Control: Beyond JNK Inhibition ...
2025-09-27
Explore the multifaceted roles of SP600125, a potent JNK inhibitor, in dissecting translational control mechanisms and kinase signaling cross-talk. This article delivers a unique, in-depth perspective on MAPK pathway inhibition and cytokine modulation in advanced disease models.
-
Annexin V-FITC/PI Apoptosis Assay Kit: Innovations in Cel...
2025-09-26
Explore how the Annexin V-FITC/PI Apoptosis Assay Kit revolutionizes apoptosis and necrosis detection in advanced cell death pathway analysis. This article uniquely extends the discussion to infectious disease and wound healing research, highlighting technical and translational advances.
-
Innovative Polyadenylation: HyperScribe™ Poly (A) Tailing...
2025-09-25
Explore how the HyperScribe™ Poly (A) Tailing Kit empowers precise polyadenylation of RNA transcripts to boost mRNA stability and translation efficiency. This article uniquely focuses on mechanistic insights and translational applications of post-transcriptional RNA processing in cutting-edge molecular biology.
-
EZ Cap Cy5 Firefly Luciferase mRNA: Enabling Quantitative...
2025-09-24
Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) advances mRNA delivery and immune engineering by combining Cap1 capping, 5-moUTP modification, and Cy5 labeling for robust translation efficiency and bioluminescence imaging. Uncover distinct mechanistic insights and quantitative assay strategies not addressed in previous content.
-
TMCB(CK2 and ERK8 inhibitor): Advancing Protein Phase Sep...
2025-09-23
Explore the unique applications of TMCB(CK2 and ERK8 inhibitor), a tetrabromo benzimidazole derivative and DMSO soluble biochemical reagent for protein interaction studies, as a molecular tool for investigating enzyme regulation and phase separation in cellular systems.
-
br Disclosure br Acknowledgments br Introduction Deeper unde
2025-03-03
Disclosure Acknowledgments Introduction Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small trpv1 that target genetic mutations known to play critical roles in the progression to metastatic disease. Mutations in epidermal growth
-
nigericin br Experimental section br Results
2025-03-03
Experimental section Results and discussion Conclusion Acknowledgements This work was financially supported by Recruitment Program of Global Experts, and the Director Foundation of XTIPC, CAS, Grant No. 2015RC011. This work was also financially supported by Natural Science Foundation of
-
During myeloid cell maturation expression of LO
2025-03-03
During myeloid cell maturation, expression of 5-LO mRNA and protein is strongly induced (60–130-fold) by calcitriol (1,25(OH)2D3) and transforming growth factor-β (TGFβ) [6,7]. The upregulation of 5-LO mRNA transcription is mainly due to transcript elongation and mRNA maturation [8,9]. Interestingly
-
Nevertheless though the LO pathway dictates the
2025-03-03
Nevertheless, though the 5-LO pathway dictates the production of lipid mediators with opposite roles in the immune reactions, like LTs and LXA4 [32], our results seemed to corroborate others that pointed to LTB4 as an outstanding mediator involved in persistent and chronic inflammatory skin diseases
-
The structure of LO is divided in two domains
2025-03-03
The structure of 5-LO is divided in two domains, the catalytic C-terminal domain and the N-terminal regulatory C2-like domain (C2ld) [59,60]. The C2ld spans the TC-E 5003 1-114 and is responsible for translocation and binding of calcium and membranes [61–63]. The catalytic domain is primarily an α-
-
A review has recently been published to evaluate the potenti
2025-03-03
A review has recently been published to evaluate the potential effects of food, alcohol and EPZ031686 juices on the pharmacokinetics and pharmacodynamics of the drugs for BPH. The authors reviewed the PubMed database during the years 1991–2015. In addition, a digital version of Stockley on drug int